Marinomed Biotech AG

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Nasal

Other Names/Subsidiaries

  • Marinomed Biotech AG
See more in Biomedtracker

Latest on Marinomed Biotech AG

Scrip

Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing

 
• By Joseph Haas, Dexter Jie Yan, Jung Won Shin, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. I-Mab Readies For Commercial Activity V

Scrip

Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results

 
• By Alaric DeArment

Aldeyra Therapeutics Inc. foresees a growing market for its allergic conjunctivitis drug reproxalap as climate change drives the already growing number of people experiencing seasonal allergies. Posi

Pink Sheet

Coronavirus Notebook: An Accidental Oxford Half Dose, And EU Finally Seals Moderna Vaccine Deal

 
• By Ian Schofield

Cheering news this week for Oxford University and AstraZeneca PLC , whose vaccine showed an overall 70% efficacy rate in Phase III trials and brought to three the number of vaccines that could be fil

Scrip

Marinomed Marches Towards Approval For Hay Fever Drug

 
• By Kevin Grogan

Buoyed by an initial public offering on the Vienna Stock Exchange in February and recent promising late-stage data for its hay fever treatment Budesolv, Austria's Marinomed Biotechnologie GmbH is en